Eylea biosimilar embarks on Phase 3 trial

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial for a biosimilar version of leading treatment Eylea (aflibercept). Read more

Upward trajectory: Eyecare sector charts recovery path

Following the COVID-19 peak, Insight issued a sentiment survey to understand the eyecare sector’s views on topics ranging from the government’s crisis response to industry confidence. Here, we reveal the findings and talk to business owners about their experiences. Read more